Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.2% – What’s Next?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares were down 6.2% during mid-day trading on Tuesday . The company traded as low as $41.81 and last traded at $42.34. 600,915 shares were traded during trading, a decline of 73% from the average session volume of 2,245,691 shares. The stock had previously closed at $45.15.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: The Phase 3 Voyage study reportedly showed that DT120 reduced anxiety symptoms by 5.4 points more than placebo on the HAM-A scale, marking the second positive late-stage study highlighted by the company. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: Coverage characterized the results as a major success for Definium’s LSD-based psychiatric drug, driving a sharp advance in the stock and improving confidence in DT120’s prospects in GAD and another potential indication. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: Needham raised its DFTX price target to $66 from $50 and maintained a Buy rating, implying substantial potential upside from the referenced $42.79 price. Investors may also be looking toward an additional September 2026 catalyst. Needham raises Definium Therapeutics price target
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting the significance of the expected trial update rather than a change in the company’s fundamentals.
• Negative Sentiment: HC Wainwright reduced multiple EPS forecasts, including its FY2026 estimate to a $3.05 loss per share from $2.10 and its FY2027 estimate to a $1.71 loss from $1.22. The revisions highlight continued operating losses and execution risk despite the encouraging clinical data.

Wall Street Analyst Weigh In

DFTX has been the topic of several research reports. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, JonesTrading increased their target price on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $57.00.

Definium Therapeutics Stock Up 4.6%

The company’s 50-day moving average is $39.06 and its 200 day moving average is $26.52. The stock has a market capitalization of $4.27 billion, a PE ratio of -12.48 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, analysts anticipate that Definium Therapeutics, Inc. will post -2.81 EPS for the current year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its holdings in shares of Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after buying an additional 6,148 shares during the period. Creative Planning lifted its holdings in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the period. JPMorgan Chase & Co. lifted its holdings in Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after acquiring an additional 2,342 shares during the period. Rhumbline Advisers boosted its position in Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.